Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models.
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
15 04 2022
15 04 2022
Historique:
received:
23
02
2021
revised:
27
08
2021
accepted:
18
02
2022
pubmed:
12
4
2022
medline:
19
4
2022
entrez:
11
4
2022
Statut:
ppublish
Résumé
Angiogenesis is an established prognostic factor in advanced breast cancer, yet response to antiangiogenic therapies in this disease remains highly variable. Noninvasive imaging biomarkers could help identify patients that will benefit from antiangiogenic therapy and provide an ideal tool for longitudinal monitoring, enabling dosing regimens to be altered with real-time feedback. Photoacoustic tomography (PAT) is an emerging imaging modality that provides a direct readout of tumor hemoglobin concentration and oxygenation. We hypothesized that PAT could be used in the longitudinal setting to provide an early indication of response or resistance to antiangiogenic therapy. To test this hypothesis, PAT was performed over time in estrogen receptor-positive and estrogen receptor-negative breast cancer xenograft mouse models undergoing treatment with the antiangiogenic bevacizumab as a single agent. The cohort of treated tumors, which were mostly resistant to the treatment, contained a subset that demonstrated a clear survival benefit. At endpoint, the PAT data from the responding subset showed significantly lower oxygenation and higher hemoglobin content compared with both resistant and control tumors. Longitudinal analysis revealed that tumor oxygenation diverged significantly in the responding subset, identifying early treatment response and the evolution of different vascular phenotypes between the subsets. Responding tumors were characterized by a more angiogenic phenotype when analyzed with IHC, displaying higher vessel density, yet poorer vascular maturity and elevated hypoxia. Taken together, our findings indicate that PAT shows promise in providing an early indication of response or resistance to antiangiogenic therapy. Photoacoustic assessment of tumor oxygenation is a noninvasive early indicator of response to bevacizumab therapy, clearly distinguishing between control, responding, and resistant tumors within just a few weeks of treatment.
Identifiants
pubmed: 35404400
pii: 694242
doi: 10.1158/0008-5472.CAN-21-0626
pmc: PMC9359720
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Hemoglobins
0
Receptors, Estrogen
0
Bevacizumab
2S9ZZM9Q9V
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1658-1668Subventions
Organisme : Cancer Research UK
ID : C14303/A17197
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C9545/A29580
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C47594/A16267
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C197/A16465
Pays : United Kingdom
Informations de copyright
©2022 The Authors; Published by the American Association for Cancer Research.
Références
Cancer Imaging. 2010 Oct 04;10 Spec no A:S74-82
pubmed: 20880784
Nat Rev Clin Oncol. 2019 Aug;16(8):469-493
pubmed: 30816337
Photoacoustics. 2019 Aug 12;15:100143
pubmed: 31463195
Eur Radiol Exp. 2018;2(1):5
pubmed: 29708213
Biochim Biophys Acta. 2016 Aug;1866(1):76-86
pubmed: 27343712
J Biomed Opt. 2012 May;17(5):056016
pubmed: 22612139
Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14325-30
pubmed: 26578779
Angiogenesis. 2014 Jul;17(3):471-94
pubmed: 24482243
Clin Cancer Res. 2011 Oct 1;17(19):6192-205
pubmed: 21788357
Mol Cancer Ther. 2009 Jul;8(7):1761-71
pubmed: 19567820
Cell Signal. 2019 Jan;53:400-412
pubmed: 30445167
Nat Rev Clin Oncol. 2011 Jun;8(6):319-20
pubmed: 21556024
J Clin Oncol. 2009 Oct 20;27(30):4966-72
pubmed: 19720913
Nat Rev Cancer. 2018 Sep;18(9):576-585
pubmed: 29891961
J Biomed Opt. 2014 Mar;19(3):36021
pubmed: 24676383
Front Mol Biosci. 2020 Jan 31;6:160
pubmed: 32118030
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Nucl Med. 2015 Dec;56(12):1942-7
pubmed: 26315834
Invest Radiol. 2016 Nov;51(11):746-755
pubmed: 27082316
Cancer Res. 2015 Jan 1;75(1):120-33
pubmed: 25381153
PLoS One. 2014 Jan 23;9(1):e86583
pubmed: 24466160
Breast. 2013 Aug;22 Suppl 2:S57-65
pubmed: 24074794
Nat Rev Cancer. 2008 Aug;8(8):592-603
pubmed: 18650835
Adv Healthc Mater. 2017 Jan;6(1):
pubmed: 27782375
Eur J Drug Metab Pharmacokinet. 2018 Apr;43(2):137-153
pubmed: 29019020
Theranostics. 2015 Jan 01;5(3):289-301
pubmed: 25553116
J Biomed Opt. 2012 Jun;17(6):061202
pubmed: 22734732
J Nucl Med. 2017 May;58(5):807-814
pubmed: 28126890
PLoS One. 2017 Mar 15;12(3):e0173693
pubmed: 28296916
Br J Cancer. 2018 Apr;118(8):1098-1106
pubmed: 29576623
Photoacoustics. 2014 Jun 27;2(3):103-10
pubmed: 25431754
PLoS One. 2016 Oct 27;11(10):e0165345
pubmed: 27788199
Photoacoustics. 2019 Jun 30;16:100134
pubmed: 31871887
Cancer Res. 2020 Dec 1;80(23):5291-5304
pubmed: 32994204
Clin Cancer Res. 2013 Jun 1;19(11):2995-3007
pubmed: 23461901
Dis Model Mech. 2019 Jul 16;12(7):
pubmed: 31337635
Cancer Res. 2016 Aug 1;76(15):4493-503
pubmed: 27325647
J Vet Diagn Invest. 2011 May;23(3):436-53
pubmed: 21908272
Cancer Treat Rev. 2017 Feb;53:98-110
pubmed: 28088074
Quant Imaging Med Surg. 2019 Feb;9(2):160-170
pubmed: 30976540
Cancer Res. 2020 Sep 1;80(17):3542-3555
pubmed: 32546631
J Cancer. 2020 May 18;11(15):4474-4494
pubmed: 32489466
J Oncol. 2012;2012:417673
pubmed: 23008712
Nat Rev Cancer. 2004 Jun;4(6):423-36
pubmed: 15170445
Cancer Res. 2018 Oct 15;78(20):5980-5991
pubmed: 30115696
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Quant Imaging Med Surg. 2019 Mar;9(3):418-426
pubmed: 31032189